Description: LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Home Page: www.lenz-tx.com
445 Marine View Avenue
Del Mar,
CA
92014
United States
Phone:
(858) 925-7000
Officers
| Name | Title |
|---|---|
| Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director |
| Mr. Shawn Olsson | Chief Commercial Officer |
| Mr. Marc G. Odrich M.D. | Chief Medical Officer |
| Mr. James W. McCollum | Co-Founder & Director |
| Mr. Daniel R. Chevallard CPA | Chief Financial Officer |
| Mr. Domenick Porfidia | Vice President of Sales |
| Mr. David Murphy | Vice President of Marketing |
| Ms. Breianna Bowen | Vice President of Human Resources |
| Mr. Marvin J. Garrett | Senior Vice President of Regulatory & Quality |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1126 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |